SLC5A2 and type 2 diabetes mellitus: According to Standards of Care in Diabetes 2025 published by American Diabetes Association, sodium glucose cotransporter 2 inhibitor (SGLT2i) was recommended to use for glycemic management and comprehensive cardiovascular risk reduction in adults with T2DM and established or high risk of cardiovascular disease (American Diabetes Association Professional Practice Committee, 2025).